Core Viewpoint - The company has successfully administered the first dose of its self-developed radiolabeled drug, 177Lu-PSMA-3D1015 (3D1015), to a patient, marking a significant milestone in its clinical research for treating PSMA-positive metastatic castration-resistant prostate cancer (mCRPC) [1] Group 1: Clinical Research Focus - The study specifically targets patients with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC) [1] - The research will systematically evaluate the core clinical value of 3D1015, focusing on the drug's safety and radiation dosimetry assessment [1] - The study aims to collect in-depth pharmacokinetic characteristics and dose exploration data of the drug in humans, providing direct clinical evidence for dose determination and risk control in subsequent registration clinical trials [1]
思路迪医药股份：新型放射性核素偶联药物3D1015首次人体给药成功